News
ORKA
63.90
+1.14%
0.72
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
Benzinga · 9h ago
Julian Harrison Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target on Strong Clinical Profile and Cash Position
TipRanks · 9h ago
Barclays Remains a Buy on Oruka Therapeutics (ORKA)
TipRanks · 11h ago
Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential
TipRanks · 22h ago
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
NASDAQ · 1d ago
Oruka Therapeutics GAAP EPS of -$0.48 beats by $0.07
Seeking Alpha · 1d ago
Oruka Therapeutics Q1 FY26 net loss widens 52% to $31.82 million
PUBT · 1d ago
Oruka's Psoriasis Data Already Priced In Unless the Quarterly Dosing Profile Surprises
Barchart · 2d ago
Healthcare stocks with A+ momentum investors are watching
Seeking Alpha · 2d ago
Halozyme beats Q1 revenue estimates, sets $1 billion buyback
Reuters · 3d ago
Weekly Report: what happened at ORKA last week (0504-0508)?
Weekly Report · 3d ago
H.C. Wainwright Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)
TipRanks · 6d ago
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
TipRanks · 05/07 06:12
BUZZ-U.S. STOCKS ON THE MOVE-Instacart, New York Times, Novavax
Reuters · 05/06 17:51
BUZZ-U.S. STOCKS ON THE MOVE-DaVita, Knight-Swift, Madrigal Pharma
Reuters · 05/06 15:50
BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber
Reuters · 05/06 13:24
Oruka licenses Halozyme Hypercon technology to develop psoriasis drug ORKA-001
PUBT · 05/06 12:11
BUZZ-Oruka rises after psoriasis drug pact using Halozyme's injection tech
Reuters · 05/06 12:10
Halozyme, Oruka sign global license to develop ORKA-001 using Hypercon technology
PUBT · 05/06 12:06
HALOZYME THERAPEUTICS INC - ORUKA TO MAKE UPFRONT AND MILESTONE PAYMENTS; HALOZYME ELIGIBLE FOR MID-SINGLE DIGIT ROYALTIES
Reuters · 05/06 12:00
More
Webull provides a variety of real-time ORKA stock news. You can receive the latest news about Oruka Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).